Skip to main content
European Commission logo print header

KWatch Glucose: A Wearable Painless Continuous Glucose Monitoring Smartwatch

Project description

A smart, painless device to track glucose levels

Only 20 % of the estimated 100 million people who should be monitoring their blood glucose levels (GL) several times a day actually do it correctly. One reason for this is that the monitoring devices used today may cause pain and are too expensive. The EU-funded K’Watch Glucose project will offer a solution to this problem by introducing to the European and US markets a novel monitoring system – K'Watch Glucose. The system, which consists of a smartwatch and a consumable patch, enables minimally invasive, continuous, painless GL self-monitoring. An innovative technology permits high accuracy of GL measurements without blood sampling thanks to a biosensor array made of micro needles. The solution will offer the first convenient, constant GL monitoring method, effectively preventing complications caused by hypoglycaemia.


Most diabetes preventable emergencies, like severe hypoglycaemia (cost of €1535.8/event in Europe), are linked to a poor self- management. Diabetes management relies on blood glucose (BG) monitoring several times a day. Only 20% of the 100M people that should monitor their glucose does it periodically and correctly. This is caused, partially, by the inconveniences of available self-monitoring devices: these devices are painful, burdensome, and expensive.
We have developed K'Watch Glucose, a minimally invasive glucose self-monitoring system embedded in a smartwatch. Our innovative technology measures glucose levels from extracted interstitial fluid (ISF), without painful blood-sampling and high accuracy (99%). This is possible thanks to SkinTaste®, a patented, calibration-free biosensor array that uses micro-needles (<0.7mm long) to collect and analyze chemical composition of the interstitial fluid. Thanks to its small size, our solution stays “invisible” to others, enabling monitoring of glucose levels anytime and anywhere, without anyone noticing.
In the Accelerator, we will prepare K’Watch Glucose for its successful launch in the European Union and in North America by validating it clinically in our target markets, certifying it as a Class 2 medical device, by pursuing its industrialisation, preparing its reimbursement and establishing a solid commercial network of distributors, insurances and users.
K’Watch Glucose could have a significant impact on preventing avoidable hypoglycaemia episode and its associated complications. Considering that we expect to have 830k active users by the end on our 5th commercialization year, K’Watch Glucose could potentially save around €1.27M per year in Europe and $0.96M in US derived just from preventing severe complications led by hypoglycaemia.
In 5 years from the Accelerator Program, we estimate a cumulative Profit of €201.1M with a ROI of 10.53 besides a clear social benefit with the recruitment of 139 new employees.

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 2 289 963,38
14 avenue de l'opera
75001 Paris

See on map

Ile-de-France Ile-de-France Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 981 412,87